

Jazz Pharmaceuticals plc
Form DEFA14A
July 18, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Section 240.14a-12

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing:

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No:

(3) Filing Party:

(4) Date Filed:

The following e-mail was sent to employees of Jazz Pharmaceuticals plc on July 18, 2016

Subject: Action Requested of Jazz Employee Shareholders Please Vote Your Shares!

Dear Jazzicians,

We are holding our 2016 Annual General Meeting of Shareholders (AGM) on August 4th, and many of you are shareholders in addition to being employees of Jazz Pharmaceuticals. ***If you were not a shareholder of Jazz Pharmaceuticals plc on June 7, 2016, the record date for the AGM, you can disregard this message.***

By now, if you were a shareholder on the record date, you should have received instructions in the mail or electronically from your bank or broker about how to vote your shares. See below for more information about E*Trade notifications.

We have a number of important proposals being voted on at the AGM. Jazz Pharmaceuticals' board of directors and management team recommend that you vote your shares FOR the election of each of the director nominees that have been nominated for re-election at the AGM, and FOR each of the other proposals that have been submitted for a shareholder vote at the AGM. Please refer to Jazz Pharmaceuticals' proxy statement for more details regarding the nominees and proposals, or reach out to Valerie Pierce, Kathee Littrell or Diane Schrick.

As a Jazz Pharmaceuticals shareholder, your vote is very important. We encourage you to read the proxy statement and vote your shares as soon as possible. If you require any assistance in voting your shares, please call Alliance Advisors, our proxy solicitor, at +1.855.973.0094.

We thank all of you for your continued support of Jazz Pharmaceuticals.

Suzanne Sawochka Hooper

Executive Vice President &

General Counsel

E*Trade Notifications:

*If you hold shares through E*Trade and receive communications electronically, you should have received an email on or close to June 30th from E*Trade with a from address of id@ProxyVote.com with the subject heading JAZZ PHARMACEUTICALS PLC Annual Meeting with instructions about how to vote your shares (please check your spam or junk folder if you did not receive it). If you do not receive communications from E*Trade electronically, you should have received instructions about how to vote your shares in the mail.*